In addition, several preclinical studies have demonstrated that agonists of the TLRs (TLR3, TLR7/8 and TLR9) in macrophages may enhance anti-tumor treatment efficacy by polarizing M0 macrophages into Th1 and M1-like TAMs and inhibiting tumor progression [45]. Here, TLR3 is linked to neoplasm.